203 related articles for article (PubMed ID: 34708255)
21. Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants.
Holze F; Erne L; Duthaler U; Liechti ME
Br J Clin Pharmacol; 2024 Jan; 90(1):200-208. PubMed ID: 37596682
[TBL] [Abstract][Full Text] [Related]
22. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
Liechti ME; Dolder PC; Schmid Y
Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
[TBL] [Abstract][Full Text] [Related]
23. Multiple phenotypes of resting-state cognition are altered in insomnia disorder.
Palagini L; Cellini N; Mauri M; Mazzei I; Simpraga S; dell'Osso L; Linkenkaer-Hansen K; Riemann D
Sleep Health; 2016 Sep; 2(3):239-245. PubMed ID: 29073428
[TBL] [Abstract][Full Text] [Related]
24. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.
Glazer J; Murray CH; Nusslock R; Lee R; de Wit H
Neuropsychopharmacology; 2023 Jan; 48(2):418-426. PubMed ID: 36284231
[TBL] [Abstract][Full Text] [Related]
25. The ARSQ 2.0 reveals age and personality effects on mind-wandering experiences.
Diaz BA; Van Der Sluis S; Benjamins JS; Stoffers D; Hardstone R; Mansvelder HD; Van Someren EJ; Linkenkaer-Hansen K
Front Psychol; 2014; 5():271. PubMed ID: 24772097
[TBL] [Abstract][Full Text] [Related]
26. Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide.
Speth J; Speth C; Kaelen M; Schloerscheidt AM; Feilding A; Nutt DJ; Carhart-Harris RL
J Psychopharmacol; 2016 Apr; 30(4):344-53. PubMed ID: 26979587
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study.
Family N; Hendricks PS; Williams LT; Luke D; Krediet E; Maillet EL; Raz S
J Psychopharmacol; 2022 Mar; 36(3):321-336. PubMed ID: 35253516
[TBL] [Abstract][Full Text] [Related]
28. LSD alters dynamic integration and segregation in the human brain.
Luppi AI; Carhart-Harris RL; Roseman L; Pappas I; Menon DK; Stamatakis EA
Neuroimage; 2021 Feb; 227():117653. PubMed ID: 33338615
[TBL] [Abstract][Full Text] [Related]
29. LSD enhances suggestibility in healthy volunteers.
Carhart-Harris RL; Kaelen M; Whalley MG; Bolstridge M; Feilding A; Nutt DJ
Psychopharmacology (Berl); 2015 Feb; 232(4):785-94. PubMed ID: 25242255
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
[TBL] [Abstract][Full Text] [Related]
31. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
Murphy RJ; Sumner R; Evans W; Ponton R; Ram S; Godfrey K; Forsyth A; Cavadino A; Krishnamurthy Naga V; Smith T; Hoeh NR; Menkes DB; Muthukumaraswamy S
Biol Psychiatry; 2023 Sep; 94(6):511-521. PubMed ID: 36997080
[TBL] [Abstract][Full Text] [Related]
32. The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial.
Yanakieva S; Polychroni N; Family N; Williams LTJ; Luke DP; Terhune DB
Psychopharmacology (Berl); 2019 Apr; 236(4):1159-1170. PubMed ID: 30478716
[TBL] [Abstract][Full Text] [Related]
33. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers.
Ramaekers JG; Hutten N; Mason NL; Dolder P; Theunissen EL; Holze F; Liechti ME; Feilding A; Kuypers KP
J Psychopharmacol; 2021 Apr; 35(4):398-405. PubMed ID: 32842825
[TBL] [Abstract][Full Text] [Related]
34. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
Schmid Y; Enzler F; Gasser P; Grouzmann E; Preller KH; Vollenweider FX; Brenneisen R; Müller F; Borgwardt S; Liechti ME
Biol Psychiatry; 2015 Oct; 78(8):544-53. PubMed ID: 25575620
[TBL] [Abstract][Full Text] [Related]
35. Time, valence, and imagination: a comparative study of thoughts in restricted and unrestricted mind wandering.
Li H; Hills T
Psychol Res; 2024 May; ():. PubMed ID: 38767718
[TBL] [Abstract][Full Text] [Related]
36. Effective connectivity changes in LSD-induced altered states of consciousness in humans.
Preller KH; Razi A; Zeidman P; Stämpfli P; Friston KJ; Vollenweider FX
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2743-2748. PubMed ID: 30692255
[TBL] [Abstract][Full Text] [Related]
37. Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration.
Avram M; Müller F; Preller KH; Razi A; Rogg H; Korda A; Holze F; Vizeli P; Ley L; Liechti ME; Borgwardt S
Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):522-532. PubMed ID: 37532129
[TBL] [Abstract][Full Text] [Related]
38. Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.
Vizeli P; Straumann I; Holze F; Schmid Y; Dolder PC; Liechti ME
Sci Rep; 2021 May; 11(1):10851. PubMed ID: 34035391
[TBL] [Abstract][Full Text] [Related]
39. Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study.
Hendricks PS; Copes H; Family N; Williams LT; Luke D; Raz S
J Psychopharmacol; 2022 Mar; 36(3):337-347. PubMed ID: 35253517
[TBL] [Abstract][Full Text] [Related]
40. The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity.
Bedford P; Hauke DJ; Wang Z; Roth V; Nagy-Huber M; Holze F; Ley L; Vizeli P; Liechti ME; Borgwardt S; Müller F; Diaconescu AO
Neuropsychopharmacology; 2023 Jul; 48(8):1175-1183. PubMed ID: 37185950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
